Efficacy and safety of nab-paclitaxel in metastatic gastric cancer: a meta-analysis-Reference-Cited by-同舟云学术

Efficacy and safety of nab-paclitaxel in metastatic gastric cancer: a meta-analysis

Published:2023-11-20 Issue: Volume: Page:
ISSN:1743-5889
Container-title:Nanomedicine
language:en
Short-container-title:Nanomedicine

Author:

Ahmad Suhana¹^ORCID,Lambuk Lidawani¹^ORCID,Ahmed Naveed²^ORCID,Mussa Ali³⁴^ORCID,Tee Vincent⁵^ORCID,Mohd Idris Ros Akmal¹^ORCID,Sahran Nur Fazimah⁵^ORCID,Chan Yean Yean²^ORCID,Hassan Rosline³^ORCID,Lee Yeong Yeh⁵⁶^ORCID,Mohamud Rohimah¹^ORCID

Affiliation:

1. Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia, 16150, Kubang Kerian, Kelantan, Malaysia

2. Department of Medical Microbiology & Parasitology, School of Medical Sciences, Universiti Sains Malaysia, 16150, Kubang Kerian, Kelantan, Malaysia

3. Department of Haematology, School of Medical Sciences, Universiti Sains Malaysia, 16150, Kubang Kerian, Kelantan, Malaysia

4. Department of Biology, Omdurman Islamic University, 14415, Omdurman, Sudan

5. Department of Internal Medicine, School of Medical Sciences, Universiti Sains Malaysia, 16150, Kubang Kerian, Kelantan, Malaysia

6. GI Function & Motility Unit, Hospital Universiti Sains Malaysia, Universiti Sains Malaysia, 16150, Kubang Kerian, Kelantan, Malaysia

Abstract

Background: Nab-paclitaxel is formulated to address several limitations of paclitaxel. Methods: A systematic review was done of several databases and a meta-analysis with a random-effects model was conducted to assess the efficacy and safety of nab-paclitaxel in metastatic gastric cancer (MGC). Results: Included studies revealed that nab-paclitaxel provides a 30.4% overall response rate and 65.7% disease control rate in MGC patients. The overall survival was 9.65 months and progression-free survival was 4.48 months, associated with the treatment line and regimen. The highest incidence of grade 3 and higher treatment-related adverse events was for neutropenia (29.9%). Conclusion: Nab-paclitaxel provides better disease response and longer survival with manageable side effects in MGC compared with paclitaxel.

Funder

Fundamental Research Grant Scheme by Ministry of Higher Education of Malaysia

Publisher

Future Medicine Ltd

Subject

Development,General Materials Science,Biomedical Engineering,Medicine (miscellaneous),Bioengineering

Link

https://www.futuremedicine.com/doi/pdf/10.2217/nnm-2022-0300

Reference30 articles.

1. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

2. Randomized phase III study of irinotecan (CPT-11) versus weekly paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 trial.

3. Phytochemical Constituents, Biological Activities, and Health-Promoting Effects of the Melissa officinalis

4. Efficacy and safety of paclitaxel with or without targeted therapy as second-line therapy in advanced gastric cancer

5. Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis